Pain Care Forum – RADARS System Update
June 14, 2012
Eric Lavonas, MD
Associate Director, Rocky Mountain Poison and Drug Center
RADARS System – 2012

- Poison Center
  - Acute Events
    - 49 Centers
    - 46 States

- Drug Diversion
  - Criminal Justice
    - 280 investigator
    - 50 states

- Opioid Tx Program (OTP)
  - Patients in Tx
    - 73 programs
    - 33 states

- SKIP
  - Survey of Key Informant Pts
    - 125 practices
    - 50 states

- College Survey
  - 2000 students
    - 50 States

- StreetRx
  - www.streetrx.com
  - Users/Buyers Crowdsourcing
    - 50 states

- Patients in Tx
  - 73 programs
    - 33 states

- Patients in Tx
  - 125 practices
    - 50 states

- States

- Investigator

- Users/Buyers

- Crowdsourcing
RADARS System – 2012

- Drugs Of Interest
  - 13 API Level Categories
    - OXYCODONE
    - HYDROMORPHONE
    - MORPHINE
    - TRAMADOL
    - METHADONE
    - HYDROCODONE
    - FENTANYL
    - TAPENTADOL
    - OXYMORPHONE
    - AMPHETAMINES
    - HEROIN
    - BUPRENORPHINE
    - METHYLPHENIDATE
  - 120 Individual Substances
  - 24 Specific Products
Reformulated OxyContin: Pre and Post-Analysis

OxyContin OC

OxyContin OP
Poison Center Program - Intentional Abuse
Population Rate for OxyContin
2008 Q4 - 2011 Q4

<table>
<thead>
<tr>
<th>Drug</th>
<th>Δ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OxyContin ORF</td>
<td>-34.4</td>
</tr>
<tr>
<td>Other Rx opioid</td>
<td>-2.8</td>
</tr>
</tbody>
</table>

Before Introduction of OxyContin-reformulated
After Introduction of OxyContin-reformulated
Drug Diversion Program
Population Rate for OxyContin
2008 Q4 - 2011 Q4

<table>
<thead>
<tr>
<th>Drug</th>
<th>Δ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OxyContin</td>
<td>-50.2</td>
</tr>
<tr>
<td>Other Rx opioid</td>
<td>-6.1</td>
</tr>
</tbody>
</table>

Before Introduction of OxyContin-reformulated
After Introduction of OxyContin-reformulated
Drug Diversion Program
OxyContin Street Price 2010 Q1 - 2011 Q4

<table>
<thead>
<tr>
<th>Drug</th>
<th>Street Price / mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>OxyContin</td>
<td>$0.83</td>
</tr>
<tr>
<td>ORF</td>
<td>$0.68</td>
</tr>
</tbody>
</table>

Original OxyContin®
- Reformulated OxyContin
Single-Ingredient Buprenorphine and Buprenorphine + Naloxone
Buprenorphine Data Comparison
RADARS System & CESAR Fax

Estimated Number of Total Methadone and Buprenorphine Reports,
U.S. Law Enforcement-Seized Drug Exhibits Analyzed by Forensic Laboratories, 2003-2010

Number of Total Methadone and Buprenorphine Cases,
RADARS System Drug Diversion Program, 2002 - 2011
Buprenorphine Abuse: Importance of Product Specificity

The RADARS® System SKIP Program-
Rates per 100,000 Population
From 1st Quarter 2010 to 4th Quarter 2011
Buprenorphine Abuse: Importance of Product Specificity

The RADARS® System SKIP Program
Rates per 100,000 Population
From 1st Quarter 2010 to 4th Quarter 2011
Buprenorphine Abuse: Importance of Product Specificity

The RADARS® System SKIP Program- Rates per 1,000 URDD
From 1st Quarter 2010 to 4th Quarter 2011
Buprenorphine Abuse: Importance of Product Specificity

The RADARS® System SKIP Program-
Rates per 1,000 URDD
From 1st Quarter 2010 to 4th Quarter 2011
Intervention Analysis: Operation UNITE
• Narcotics Investigations
  – Arrested over 3700 individuals
  – Total value of seized substances = $11.6 Million

• Treatment
  – Voucher program providing over $7.3 million for residential treatment
  – Drug Court created to support recovery and education rather than incarceration

• Education
  – 30 Community Coalitions
  – Drug Free Workplace Trainings
  – UNITE Service Corps volunteers to tutor, mentor, and educate
RADARS System Analysis of OperationUNITE

The RADARS® System Poison Center Program – Intentional Abuse Prescription Opioid Mentions
Percent Change in Rates: Kentucky v. Rest of United States
Population Rate 2008 Q4 through 2011 Q3 by time period

The RADARS® System Poison Center Program – Intentional Abuse Prescription Opioid Mentions
Percent Change in Rates: Kentucky v. Rest of United States
URDD Rate 2008 Q4 through 2011 Q3 by time period
RADARS® System Summary

• 10 years of data
• Capture data on multiple facets of drug abuse (mosaic approach)
• Product Specificity
  – Over 120 drugs of interest
  – Critical in understanding full scope of misuse and abuse issues
• Offer comparator data to other prescription opioids over the same period of time
• Provide data that are timely and comprehensive